What Комбиспазм treats: Main Uses and Benefits

Комбиспазм is commonly used for managing pain and muscle spasms. Its primary role is to provide symptomatic relief by addressing symptoms related to physical discomfort and heightened physiological activity. It is applied in contexts where temporary, short-term assistance in managing distressing symptoms is needed to help maintain functional stability.

The medication helps address symptom clusters that may become intense or disruptive, especially those linked to sudden, involuntary muscle contractions. This is commonly used in conditions presenting with acute episodes, such as biliary colic, intestinal colic, renal colic, and spasmodic dysmenorrhea (painful menstrual cramps). The medication is also relevant for easing challenging symptoms related to physical discomfort, like general aches and pain.

Quick Fact: Relief for Acute Spasmodic Discomfort

The support offered contributes to improved day-to-day comfort during symptomatic periods, helping patients cope more steadily with symptom fluctuations. The medication is relevant when symptoms become temporarily overwhelming, assisting with maintaining functional stability.

Regulatory References

1. Sanofi Product Information on Dicyclomine and Paracetamol

The eligibility for using Комбиспазм, a fixed-dose combination of Acetaminophen and Dicyclomine, is strictly defined by regulatory contraindications and population restrictions tied to the components. Use is generally established for adults and adolescents aged 12 years and older, provided no contraindications exist.

Absolute Contraindications

The medicine must not be used in certain patient groups, including infants under six months of age and nursing mothers. Use is also prohibited for patients with pre-existing severe conditions. These include severe hepatic impairment, due to the risk associated with Acetaminophen, and conditions sensitive to the anticholinergic Dicyclomine component. Such prohibitions apply to patients with obstructive diseases (gastrointestinal, urinary tract, or obstructive glaucoma), Myasthenia Gravis, or severe ulcerative colitis.

Restricted and Conditional Use

Safety and effectiveness have not been established for children between six months and twelve years of age, and use is not recommended for this group. Geriatric patients require caution due to increased susceptibility to anticholinergic effects. Use also requires caution and clinical monitoring in patients with non-severe renal or hepatic impairment, or if used during pregnancy, where use is considered conditional.

Interactions with other medicines and products

Official regulatory information for Комбиспазм (Acetaminophen/Dicyclomine) outlines several important drug interactions based on the documented properties of its active ingredients.

Documented Pharmacological Interactions

Interaction Type	Interacting Substances/Conditions
Additive Anticholinergic Effects	Other Anticholinergic Drugs, Opioid Agonists, and certain Antihistamines. These combinations carry an increased risk of severe effects like urinary retention and constipation.
Contraindicated Combination	Pramlintide is formally contraindicated due to the potential for synergistic and dangerous inhibition of gastrointestinal motility.
Antagonized Effects	Antiglaucoma Agents and Prokinetics (e.g., Metoclopramide) may have their intended actions reduced by Dicyclomine.

---

Pharmacokinetic and Exposure Constraints

Interactions involving changes in drug concentration or metabolism are also officially documented:

• CYP2E1 Inducers: Substances that induce the CYP2E1 enzyme, such as Ethanol (Alcohol), can increase the formation of the toxic metabolite of Acetaminophen, raising the risk of hepatotoxicity.
• Anticoagulants: Chronic use of Acetaminophen may officially increase the International Normalized Ratio (INR) in patients taking Sodium Warfarin, requiring monitoring.
• Digoxin: Dicyclomine may increase the absorption and serum concentration of slow-dissolving Digoxin dosage forms.
• Antacids: The label advises that simultaneous administration of Antacids should be avoided as they may interfere with Dicyclomine absorption.

Population-specific interaction cautions are noted for patients with severe renal impairment or active liver disease, where interaction severity may be heightened.

Комбиспазм modulates physiological processes through the synergistic action of its two components: Metamizole and Pitofenone.

Molecular Targeting and Pathway Modulation

Metamizole functions primarily as an inhibitor of cyclooxygenase (COX) activity, specifically targeting COX-1 and COX-2 enzymes in the central and peripheral nervous systems. This inhibition reduces the biosynthesis and release of prostaglandins, which are key lipid mediators involved in cellular signaling. The resulting decrease in prostaglandin levels modifies the excitability of thermoregulatory centers and peripheral nociceptors, thereby influencing the cellular response to stimuli.

Pitofenone acts as a muscarinic acetylcholine receptor (mAChR) antagonist, possessing structural characteristics similar to papaverine. Its action is directed at the smooth muscle cell membrane. By binding to mAChRs, Pitofenone interrupts the signaling cascade that typically leads to smooth muscle contraction. This block promotes the cellular accumulation of cyclic adenosine monophosphate (cAMP), which, in turn, facilitates the dephosphorylation of myosin light chains.

System-Level Physiological Consequence

The combined molecular actions result in a dual physiological effect. The reduction of prostaglandin-mediated signaling modifies afferent neuronal input. Simultaneously, the Pitofenone-induced reduction in intracellular calcium flux leads to the systemic relaxation of smooth musculature, particularly in visceral organs.

Administration Route and Dosing

Комбиспазм is an oral, Fixed-Dose Combination (FDC) preparation intended for systemic administration. The approved route of administration is strictly oral, meaning the tablet must be swallowed whole with liquid. The standard single dose for adults is one tablet, which delivers a pre-set combination of 500 mg Acetaminophen and 20 mg Dicyclomine Hydrochloride.

Frequency and Maximum Limits

The official administration regimen permits the single dose to be taken up to four times daily (q.i.d.). Procedural instructions mandate that a minimum interval of four to six hours must be maintained between successive intakes to prevent cumulative exposure. It is necessary to adhere to a strict daily ceiling of 4 tablets over a 24-hour period. This maximum limit ensures that the total daily dose of the Acetaminophen component remains well within the prescribed limits for combination products.

Contextual Use and Population Rules

While specific preparation is not required, the tablet is typically administered with or around food, a high-level contextual pattern associated with the intake of antispasmodic agents. Regarding patient population boundaries, the product is officially not approved for administration in pediatric patients under 12 years of age, setting a firm, label-based constraint. The duration of administration is limited to short-term, symptomatic use to address acute periods of discomfort, consistent with its operational definition.

Комбиспазм: Recent Clinical Evidence

Evidence for use in Acute Visceral Pain and Colic

The fixed-dose combination was studied for conditions characterized by acute, involuntary muscle contractions and pain, such as intestinal, biliary, and renal colic. Research in this area primarily examined the combination in the context of acute spasmodic pain, detailing patient groups studied in Randomized Controlled Trials (RCTs) and comparative studies. Research monitored patients over defined, short time intervals, with assessments focused on how symptom intensity changed and the rate at which participants reported symptom change. The evidence quality varies across studies, and comparative evidence is lacking against all modern standards, providing limited insight beyond the immediate acute phase of episodes where symptoms become more noticeable.

Evidence for use in Spasmodic Dysmenorrhea

The evidence base for painful menstrual cramps, which are conditions involving periods of heightened symptoms, involves short-term comparative trials. This research was evaluated in women and adolescents experiencing primary dysmenorrhea. Researchers explored how patients responded during a single menstrual cycle, with outcomes studies monitored being measurements of perceived discomfort and overall symptom change. Sample sizes were modest in initial studies, and the evidence provides limited data for long-term outcomes regarding the repeated use across multiple cycles.

Long-Term Studies and Follow-up Duration

The evidence available mainly describes the effects of the medicine within acute, defined time frames. The follow-up durations for trials was studied for acute outcomes related to episodic or acute changes and were typically brief. Long-term effects are not fully established since trials did not typically monitor patients for extended periods to evaluate sustained symptom patterns. This means certainty about chronic or maintenance use remains low.

Evidence in Specific Patient Populations

The majority of clinical trials for this combination was evaluated in the general adult population. Data for certain groups remain insufficient due to their exclusion from initial pivotal trials. For instance, the scope of research is limited in older adults, and subgroup findings are uncertain in children and adolescents. Results apply only to the populations studied, and the evidence does not allow for broad generalization outside of those groups.

What is Still Uncertain About the Research for Комбиспазм

This fixed-dose combination was studied for its role in managing conditions marked by functional limitations, but several research gaps exist. Comparative evidence is lacking to fully establish its role against all current standard-of-care treatments. The evidence quality varies across studies, and findings were mixed in some aspects, which contributes to the fact that certainty remains low in certain areas of use. Further research is ongoing to provide context and refine the understanding of how the medicine may influence outcomes related to physical discomfort across a wider range of patients and over longer periods.

Key Studies & References

1. Fixed Dose Combination (FDC) Concept in Pharmaceuticals - Review Article
2. BARALGAN NU (Dicyclomine Hydrochloride and Paracetamol Tablets) Product Information - Supporting Indications

Common questions about Комбиспазм (FAQ)

---

Q: What is Комбиспазм used for besides headache relief?

A: According to official product information, the Dicyclomine component of this medicine is indicated to treat symptoms of functional bowel or irritable bowel syndrome (IBS). Its primary uses are directed at conditions with accompanying muscle spasms (cramps) and pain in the digestive system. The combination is typically studied for acute discomfort where cramping is a primary component.

Q: What does the 'spasm' part of Комбиспазм mean for pain relief?

A: The 'spasm' part refers to the action of the antispasmodic ingredient, Dicyclomine. This component works by inhibiting chemical activity (acetylcholine) that causes the walls of organs like the intestines to contract. This process helps to relax smooth muscles, thereby directly reducing painful cramping and muscle tension that contribute to discomfort.

Q: Does Комбиспазм have any effect on blood pressure?

A: Official warnings state that the Dicyclomine component should be used with caution in patients with certain conditions, including high blood pressure (hypertension). Additionally, certain documented interactions with other medicines can be associated with effects such as low blood pressure (hypotension).

Q: Can Комбиспазм affect my ability to drive or operate machinery?

A: Official warnings indicate that activities requiring mental alertness, such as driving a car or operating heavy machinery, should be avoided until an individual knows how the medicine affects them. This caution is advised due to the potential for side effects such as drowsiness, dizziness, or blurred vision.

Q: What should I do if I miss a dose of Комбиспазм?

A: Official administration instructions address missed doses by advising that individuals should not double their dose to make up for a missed one. Regulatory guidance dictates skipping a dose if too much time has passed and resuming the regular schedule.

Q: Is it possible to become dependent on Комбиспазм?

A: The active components are not classified as controlled substances or dependence-producing in the same way as narcotics. However, some regulatory literature and case reports note that when the Dicyclomine component is not used judiciously, rare instances of misuse and dependence have been reported.

Q: Can Комбиспазм be taken with common cold and flu medicines?

A: Regulatory documents caution against combining this medication with other common cold or flu remedies because many also contain the active ingredient Acetaminophen (Paracetamol). Combining them can easily lead to exceeding the maximum daily limit of the analgesic component, which carries a risk of serious liver damage.

Q: What ingredients in Комбиспазм can cause an allergic reaction?

A: Official product information advises that the medicine can cause symptoms of a serious allergic reaction. This may include rash, itching/swelling of the face, tongue, or throat. Patients are generally advised to stop use and seek immediate medical help if these symptoms are experienced.

Q: Is Комбиспазм available over the counter, or is a prescription required?

A: The active component Dicyclomine Hydrochloride is classified as a Prescription-only drug by regulatory authorities like the FDA. Therefore, the combination product generally requires a valid prescription for dispensation.

Q: Why is Комбиспазм sometimes prescribed for stomach cramps?

A: The drug is prescribed for stomach cramps because its antispasmodic component, Dicyclomine, is designed to target the smooth muscles in the intestines. By blocking key signals (acetylcholine), the medicine helps these intestinal muscles to relax, which directly relieves the painful spasms and cramping that characterize conditions like irritable bowel syndrome (IBS).

Q: What makes Комбиспазм different from a standard acetaminophen or ibuprofen tablet?

A: This medication is a unique fixed-dose combination because it contains both an analgesic (Acetaminophen) and an antispasmodic (Dicyclomine). Standard single-ingredient tablets like Acetaminophen or Ibuprofen are primarily pain relievers. The added antispasmodic component allows this product to specifically address muscle spasms and cramping in addition to general pain.

Q: Is it normal to feel a bit restless after taking Комбиспазм?

A: While drowsiness and dizziness are commonly reported side effects, regulatory sources also document less frequent effects involving the central nervous system. These can include feelings of anxiety, excitement, or nervousness, which a user might describe as restlessness.

Q: Does Комбиспазм interact with any common herbal supplements?

A: Official regulatory guidance often cautions that a medication should be used with care when taken alongside herbal products. While specific common supplements are not consistently listed in the documents, this general caution is advised due to the potential for unforeseen interactions that could alter how the medicine works or increase side effects.

Q: Is there a risk of withdrawal symptoms if I stop taking Комбиспазм suddenly?

A: While the medication is not generally associated with withdrawal symptoms, case reports involving chronic misuse have noted certain effects upon sudden discontinuation. These effects have been described as involving symptoms like apprehension, restlessness, and headache.

Q: Can Комбиспазм cause stomach irritation?

A: Official documentation reports that common side effects associated with this medication include those involving the gastrointestinal system. These effects can include upset stomach, nausea, vomiting, and abdominal bloating.

Q: Can I take Комбиспазм if I am already taking medication for anxiety or depression?

A: Regulatory sources advise using Dicyclomine with caution if a patient is also taking certain medications for mood disorders, including some antipsychotics and antidepressants (such as SSRIs). This is due to the potential for an increase in side effects like drowsiness, confusion, or memory problems.

Q: Does Комбиспазм contain any caffeine or stimulating substances?

A: The active ingredients are documented as Acetaminophen and Dicyclomine. Official regulatory ingredient lists for the final product formulation do not typically include caffeine or other specific stimulating substances.

Q: Does Комбиспазм help with muscle pain?

A: The antispasmodic component primarily works to relax smooth muscles, which are the involuntary muscles found in organs like the intestines, bladder, and bile ducts. Its regulatory indication focuses on spasms in the stomach and intestines. This action is distinct from relieving skeletal muscle pain, which is the type of muscle pain commonly associated with exercise or injury.

Q: Are there any special considerations for people with heart problems using Комбиспазм?

A: Official warnings state that the Dicyclomine component requires caution when administered to patients with certain cardiovascular issues. These conditions include an abnormally fast heart rate (tachyarrhythmia), congestive heart failure, or diagnosed coronary heart disease.

Q: Does Комбиспазм affect sleep patterns?

A: The medicine can affect sleep patterns because drowsiness (somnolence) is listed as a common side effect in regulatory documents. Less frequently, side effects such as difficulty falling asleep or staying asleep (insomnia) are also reported, indicating potential effects on the quality and pattern of sleep.

Q: Can I use Комбиспазм if I have a history of peptic ulcers?

A: Regulatory documents advise that the Dicyclomine component should be used with caution in combination with certain other medicines, such as potassium supplements. This warning exists because the combination can intensify existing stomach irritation and potentially raise the risk of stomach ulceration.

The storage and disposal of Комбиспазм (Acetaminophen and Dicyclomine tablets) are strictly governed by regulatory requirements to ensure product stability and safety.

Required Storage Conditions

Condition	Regulatory Requirement
Temperature	Store at a temperature not exceeding 30 C (86 F).
Environmental	Must be protected from light and moisture.
Packaging	Keep the medicine in its original container and ensure it is tightly closed.

Child Safety and Handling

This medication must be kept out of the sight and reach of children as a mandatory regulatory precaution. The tablets should not be frozen.

Disposal Instructions

Unused or expired Комбиспазм must not be disposed of via household waste or wastewater (flushing). Official instructions require the return of unused product to a pharmacy or the use of a regulated local drug take-back program.